High-Sensitivity Troponin I (TnIH) Assay
Actionable insights for acute myocardial infarction diagnosis and future risk assessment†
In acute care, every minute matters. Clinicians need reliable cardiac insights that support rapid triage, confident decision making, and efficient patient pathways.
The Atellica IM High-Sensitivity Troponin I assay provides clinically meaningful troponin I results that aid in accurately detecting acute myocardial infarction and support assessment of future risk. By combining diagnostic performance with prognostic insight, the assay helps clinicians identify patients who may be at increased risk for future death and adverse cardiovascular events for up to one year1,2.
Designed for today’s high-pressure emergency and cardiac care settings, the Atellica IM TnIH assay helps laboratories and clinicians deliver timely, trusted results that support faster decisions, more informed care planning, and greater confidence across the patient journey.
Benefits
- Supports confidence in diagnosis when every minute matters, with highly precise results that meet IFCC definitions for high‑sensitivity cardiac troponin
- Delivers reliable performance at low concentrations and across critical clinical decision points
- Aids faster, evidence‑based triage to improve patient flow and optimize emergency care
- OUS Only: Facilitates rapid rule‑in / rule‑out of suspected NSTEMI using validated 0/1‑hour and 0/2‑hour assessment pathways2†
- Results in as little as 10 minutes to support rapid clinical decision making
- Truly automated STAT testing without compromise – no manual workarounds or disruption to routine workflows
- Automatically prioritizes STAT samples to minimize hands on time and avoid interruptions to routine testing
- Balances urgent testing demand with high throughput efficiency for consistent turnaround times
- Seamlessly integrates into everyday lab workflows on Atellica IM and Atellica CI Analyzers
- Extends insight beyond acute diagnosis with a future focused approach to cardiac care
- Enables risk assessments for all cause mortality (ACM) and major adverse cardiovascular events (MACE) for up to one year
- Supports advanced cardiac risk assessment from the Emergency Department to help guide long term patient management
- Delivers actionable prognostic metrics to help inform follow up strategies and care planning
- Optimizes care pathways across the continuum – from initial evaluation through post-discharge management - to support potentially improved outcomes well beyond the initial visit
Technical Details
Assay Specifications
Sample Type
Serum and Lithium heparin plasma
Analytical Measuring Range
2.50 – 25,000 ng/L
Sample Volume
100 µL
System Availability
Atellica Solution
Automated STAT troponin I results with high precision across the assay range and with access to a comprehensive cardiac assay menu
ADVIA Centaur CP, XP, XPT
Integrates TnIH testing onto a comprehensive immunoassay platform
Evidence
“The new Atellica IM TnIH indication helps us predict which patients may be on the cusp of a major cardiac event. We learned that nearly 50% of the patients that presented with elevated TnIH results, and a history of cardiac events are at risk for heart attack and/or death. Now this test, in combination with a robust clinical assessment, can inform physicians on an immediate and long-term management of patients to reduce risks for adverse events.” (U.S. only)
Related Products
Natriuretic Peptides
Timely and accurate diagnosis of heart failure is crucial for providing appropriate and effective treatment - and ultimately saving lives. With BNP and NT-proBNP testing options, labs can choose the natriuretic peptide marker that best aligns with their clinical protocols, workflows, and care pathways.